Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457970 | 0.84 | PTGS2 (0.44) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL1305157 | 0.83 | PTGS2 (0.43) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL14542318 | 0.83 | PTGS2 (0.46) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL21150370 | 0.81 | PTGS2 (0.42) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL459830 | 0.81 | PTGS2 (0.42) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL7638931 | 0.79 | PTGS2 (0.45) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL6248683 | 0.79 | PTGS2 (0.45) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL14026086 | 0.78 | PTGS2 (0.44) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL16502266 | 0.78 | ALDH1A1 (0.42) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A | |
| SCHEMBL6668536 | 0.77 | PTGS2 (0.46) | PTGS2ALDH1A1TSHRTDP1TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072033-B2 | N-(phosphinoalkyl)-N-(thioalkyl)amine derivative, method for producing same, and metal complex thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20170233418-A1 | N-(PHOSPHINOALKYL)-N-(THIOALKYL)AMINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-8053604-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | SPERA PHARMA, INC. (JP) | 2010-05-20 | — | — | US | disclosed |
| US-7678942-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| EP-1318156-B1 | Novel asymmetric phosphine ligand | TAKASAGO PERFUMERY CO LTD (JP) | 2010-01-20 | — | — | EP | disclosed |
| EP-1568701-B1 | TRANSITION METAL COMPLEX HAVING DIPHOSPHINE COMPLEX AS LIGAND | TAKEDA PHARMACEUTICAL (JP) | 2010-01-20 | — | — | EP | disclosed |
| EP-1452537-B1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7135582-B2 | Transition metal complex having diphosphine compound as ligand | TAKEDA PHARMACEUTIACAL COMPANY LIMITED (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060094887-A1 | Transition metal complex having diphosphine compound as ligand | SPERA PHARMA, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1568701-A1 | TRANSITION METAL COMPLEX HAVING DIPHOSPHINE COMPLEX AS LIGAND | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6730629-B2 | HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20030139285-A1 | Novel asymmetric phosphine ligand | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1318156-A1 | Novel asymmetric phosphine ligand | Takasago International Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233418-A1 | N-(PHOSPHINOALKYL)-N-(THIOALKYL)AMINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND METAL COMPLEX THEREOF | NSFL1C, TST, NCL | PTGS2 821/4885ALDH1A1 1341/4885TSHR 1890/4885 |
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | H1-10, ITPA, RER1 | PTGS2 3572/4885ALDH1A1 4580/4885TSHR 1063/4885 |
| US-20060094887-A1 | Transition metal complex having diphosphine compound as ligand | TERT, AP1M1, AP2M1 | PTGS2 4163/4885ALDH1A1 4339/4885TSHR 1651/4885 |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | BACE1, H1-10, PRMT1 | PTGS2 2985/4885ALDH1A1 2206/4885TSHR 1972/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | PTGS2 3590/4885ALDH1A1 4580/4885TSHR 1089/4885 |
| US-20030139285-A1 | Novel asymmetric phosphine ligand | PHOSPHO1, PAPSS1, PPM1F | PTGS2 3996/4885ALDH1A1 2528/4885TSHR 2674/4885 |
| US-10072033-B2 | N-(phosphinoalkyl)-N-(thioalkyl)amine derivative, method for producing same, and metal complex thereof | NSFL1C, TST, NCL | PTGS2 821/4885ALDH1A1 1341/4885TSHR 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.